Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

17.310
+0.5103.04%
Volume:3.11M
Turnover:52.94M
Market Cap:46.03B
PE:11.68
High:17.310
Open:16.800
Low:16.670
Close:16.800
52wk High:28.232
52wk Low:14.505
Shares:2.66B
HK Float Shares:540.97M
Volume Ratio:0.53
T/O Rate:0.58%
Dividend:0.45
Dividend Rate:2.60%
EPS(LYR):1.482
ROE:7.04%
ROA:1.53%
PB:0.80
PE(LYR):11.68
PS:0.93

Loading ...

Fosun Pharma Subsidiary Secures NMPA Green Light for Pediatric Constipation Treatment

Bulletin Express
·
Aug 03

Shanghai Fosun Pharma - Drug Registration Application for Empagliflozin & Metformin Hydrochloride Sustained-Release Tablets(Iii)Approved by Nmpa

THOMSON REUTERS
·
Aug 03

Shanghai Fosun Pharma - Registration Application for Polyethylene Glycol (3350) and Electrolytes Powder Approved by Nmpa

THOMSON REUTERS
·
Aug 03

Shanghai Fosun Pharmaceutical Secures Regulatory Approval for Diabetes Combination Drug

Stock News
·
Aug 03

Sinopharm Group Stock Falls 1.5% in Hong Kong

Dow Jones
·
Jul 31

Fosun Pharma's investment fund successfully completes registration with securities authorities

Stock News
·
Jul 29

Sinopharm Group Stock Climbs 2.6% in Hong Kong

Dow Jones
·
Jul 29

Sinopharm Group Stock Climbs 2.0% in Hong Kong

Dow Jones
·
Jul 27

Fosun Pharma Gains Approval for Clinical Trial of Parkinson's Disease Treatment DM1001

Deep News
·
Jul 26

Fosun Pharma Unit Gets China Clinical Trial Approval for Parkinson's Drug

MT Newswires Live
·
Jul 24

Shanghai Fosun Pharma - Approval from National Medical Products Administration for Clinical Trial of Dm1001 Formulation

THOMSON REUTERS
·
Jul 24

Fosun Pharma Subsidiary Gains Green Light for DM1001 Drug Trial in Parkinson's Treatment

Stock News
·
Jul 24

Sinopharm Group Stock Falls 1.9% in Hong Kong

Dow Jones
·
Jul 22

Sinopharm Group Stock Slides 1.7% in Hong Kong

Dow Jones
·
Jul 21

Fosun Pharma Achieves Fourth Consecutive Year on China's Best Managed Companies List

Deep News
·
Jul 20

Sinopharm Group Stock Climbs 2.1% in Hong Kong

Dow Jones
·
Jul 16

Fosun Pharma Receives NMPA Clearance to Begin Phase I Trial of siRNA Candidate FXR0906 for Hypertriglyceridemia

Bulletin Express
·
Jul 15

Shanghai Fosun Pharma - Unit Got Approval from Nmpa China for Clinical Trial of Fxr0906 for Treatment of Hypertriglyceridemia

THOMSON REUTERS
·
Jul 15

Fosun Pharma's Subsidiary Receives Approval for FXR0906 Injection Clinical Trial

Stock News
·
Jul 15

Sinopharm Group Stock Rises 2.6% in Hong Kong

Dow Jones
·
Jul 15